All In Biotech

Drug Trial Radar · NCT01173939

Primary Prevention of Major Adverse Cardiac Events (MACE) With Standard and Intensive Statin Treatment in Patients With Diabetes: Survival and Cardiovascular Event Assessments

Primary Prevention of MACE With Standard and Intensive Statin Treatment in Hypercholesterolemia Patients With Concomitant Diabetes and Hypertension

Last checked: Nov 20, 2026Latest source record: Jun 1, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 10,000 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

10,000

Planned (sponsor's estimate)

Start

Jul 2010

Primary completion

Jun 2014

Sponsor

Lead sponsor
Positive Trial GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 2, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to compare the effect of standard treatment (target LDL-C level: \<120 mg/dL (JASGL 2007 target level)) and intensive treatment (target LDL-C level: \<70 mg/dL) in the prevention of major adverse cardiac events (MACE) in hypercholesterolemia patients with concomitant type 2 diabetes and hypertension.

Conditions

  • Hypercholesterolemia
  • Type 2 Diabetes
  • Hypertension

Interventions

  • PravastatinDrug

    5 mg/day or 10 mg/day of pravastatin will be administered orally for 36 months, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<120 mg/dL (JASGL 2007 target level) as quickly as possible. (Maximum dose increase of pravastatin: 20 mg/day)

  • RosuvastatinDrug

    5 mg/day or 10 mg/day of rosuvastatin will be administered orally for 36 months based on the LDL-C level of the subject, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<70 mg/dL as quickly as possible. (Maximum dose increase to rosuvastatin: 20 mg/day)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MACE (time to event): MACE (time to event): myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal/nonfatal cerebrovascular accident, peripheral arteriopathy, aortic eventTime frame: At baseline
  2. MACE (time to event): MACE (time to event): myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal/nonfatal cerebrovascular accident, peripheral arteriopathy, aortic eventTime frame: 1 month after treatment initiation
  3. MACE (time to event): MACE (time to event): myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal/nonfatal cerebrovascular accident, peripheral arteriopathy, aortic eventTime frame: 3 month after treatment initiation
  4. MACE (time to event): MACE (time to event): myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal/nonfatal cerebrovascular accident, peripheral arteriopathy, aortic eventTime frame: 6 month after treatment initiation
  5. MACE (time to event): MACE (time to event): myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal/nonfatal cerebrovascular accident, peripheral arteriopathy, aortic eventTime frame: 12 month after treatment initiation
  6. MACE (time to event): MACE (time to event): myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal/nonfatal cerebrovascular accident, peripheral arteriopathy, aortic eventTime frame: 36 month after treatment initiation
  7. MACE (time to event): MACE (time to event): myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal/nonfatal cerebrovascular accident, peripheral arteriopathy, aortic eventTime frame: At the end of the study or discontinuation up to 4 years

Locations

317 sites in 1 country. Site status is shown where the registry gives one.

  • Fukushi Clinic

    Aomori, Japan

  • Kashiwagi Clinic

    Ayase, Japan

  • Hayashi Diabetes Clinic

    Chigasaki, Japan

  • Uchiyama Clinic

    Jōetsu, Japan

  • Nitta Medical Clinic

    Kamiinagun, Japan

  • Imai Clinic

    Kawasaki, Japan

  • Tani Clinic

    Kitakyushu, Japan

  • Marumo Clinic

    Koganei, Japan

  • Ihara Clinic

    Kyoto, Japan

  • Goko-Hospital

    Matsudo, Japan

  • Satou Clinic

    Mooka, Japan

  • Iino Clinic

    Nirasaki, Japan

  • Miura Clinic

    Osaka, Japan

  • Kuroda Iin

    Ōtsuki, Japan

  • Sasaki Clinic

    Sendai, Japan

  • Kamata Clinic of Internal Medicine

    Shiki, Japan

  • Nishikawa Clinic

    Shimoda, Japan

  • Satou Iin

    Shimoinagun, Japan

  • Kumagai Clinic

    Shinshiro, Japan

  • Suzuki Clinic

    Toyokawa, Japan

  • Benibana Clinic

    Yamagata, Japan

  • Fujimi Clinic

    Yokohama, Japan

  • Hongo Clinic

    Yokohama, Japan

  • Jiyukai Yamada Naika

    Yokohama, Japan

  • Shonan Ochanomizu Clinic

    Yokohama, Japan

  • Tani Clinic Internal Medicine, Allergology & Rheumatology

    Yokohama, Japan

  • Hiramitsu Heart Clinic

    Nagoya, Aichi Pref., Japan

  • Medical Dock&Clinic

    Nagoya, Aichi Pref., Japan

  • Matsuno Medical Clinic

    Iyo Gun, Ehime Pref., Japan

  • Ishite Matsumoto Naika Junkanki Clinic

    Matsuyama, Ehime Pref., Japan

  • Ehime Medical CO-OP Izumigawa Clinic

    Niihama, Ehime Pref., Japan

  • Tsugawa Internal Medicine Clinic

    Echizen, Fukui Pref., Japan

  • Fukui Chuo Clinic

    Fukui, Fukui Pref., Japan

  • Koshino Clinic

    Sakai, Fukui Pref., Japan

  • Fukuoka University Chikushi Hospital

    Chikushino-shi, Fukuoka Pref., Japan

  • Saiseikai Futsukaichi Hospital

    Chikushino-shi, Fukuoka Pref., Japan

  • Abies Clinic

    Fukuoka, Fukuoka Pref., Japan

  • Hirano Medical Clinic

    Fukuoka, Fukuoka Pref., Japan

  • Naitoh Clinic

    Fukuoka, Fukuoka Pref., Japan

  • Saku Hospital

    Fukuoka, Fukuoka Pref., Japan

Showing 40 of 317 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.